Recurrent germline variant in ATM associated with familial myeloproliferative neoplasms.
Evan M BraunsteinEddie ImadaSergiu PascaShiyu WangHang ChenCamille AlbaDan N HupaloMatthew WilkersonClifton L DalgardJack Y GhannamYujia LiuLuigi MarchionniAlison R MoliternoChristopher S HouriganLukasz P GondekPublished in: Leukemia (2022)
Genetic predisposition (familial risk) in the myeloproliferative neoplasms (MPNs) is more common than the risk observed in most other cancers, including breast, prostate, and colon. Up to 10% of MPNs are considered to be familial. Recent genome-wide association studies have identified genomic loci associated with an MPN diagnosis. However, the identification of variants with functional contributions to the development of MPN remains limited. In this study, we have included 630 MPN patients and whole genome sequencing was performed in 64 individuals with familial MPN to uncover recurrent germline predisposition variants. Both targeted and unbiased filtering of single nucleotide variants (SNVs) was performed, with a comparison to 218 individuals with MPN unselected for familial status. This approach identified an ATM L2307F SNV occurring in nearly 8% of individuals with familial MPN. Structural protein modeling of this variant suggested stabilization of inactive ATM dimer, and alteration of the endogenous ATM locus in a human myeloid cell line resulted in decreased phosphorylation of the downstream tumor suppressor CHEK2. These results implicate ATM, and the DNA-damage response pathway, in predisposition to MPN.
Keyphrases
- dna damage response
- dna repair
- dna damage
- early onset
- copy number
- genome wide association
- prostate cancer
- end stage renal disease
- genome wide
- endothelial cells
- ejection fraction
- newly diagnosed
- peritoneal dialysis
- bone marrow
- immune response
- dendritic cells
- young adults
- protein kinase
- oxidative stress
- pluripotent stem cells
- patient reported